Sernova Corp. (SVA.TO)
CAD 0.23
(0.0%)
CAD 0.23
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -445.55 Thousand CAD | -1.26% |
| 2022 | -439.99 Thousand CAD | -64.67% |
| 2021 | -267.2 Thousand CAD | -18.64% |
| 2020 | -225.23 Thousand CAD | -266.38% |
| 2019 | -61.47 Thousand CAD | 4.73% |
| 2018 | -64.52 Thousand CAD | -61.86% |
| 2017 | -39.86 Thousand CAD | -427.05% |
| 2016 | -7564.00 CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 80.3 Thousand CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | -100.0% |
| 2005 | 5284.00 CAD | -88.07% |
| 2004 | 44.27 Thousand CAD | -66.64% |
| 2003 | 132.74 Thousand CAD | 685.65% |
| 2002 | 16.89 Thousand CAD | -79.22% |
| 2001 | 81.32 Thousand CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -104.25 Thousand CAD | 13.37% |
| 2024 Q3 | -162.78 Thousand CAD | -58.37% |
| 2024 Q2 | -102.79 Thousand CAD | 1.4% |
| 2023 Q4 | -120.33 Thousand CAD | -9.82% |
| 2023 Q2 | -108.66 Thousand CAD | 57.45% |
| 2023 Q3 | -109.57 Thousand CAD | -0.84% |
| 2023 Q1 | -255.35 Thousand CAD | -117.1% |
| 2023 FY | -445.55 Thousand CAD | -1.26% |
| 2022 FY | -439.99 Thousand CAD | -64.67% |
| 2022 Q3 | -116.61 Thousand CAD | -4.11% |
| 2022 Q1 | -93.74 Thousand CAD | -10.63% |
| 2022 Q2 | -112.01 Thousand CAD | -19.48% |
| 2022 Q4 | -117.62 Thousand CAD | -0.86% |
| 2021 FY | -267.2 Thousand CAD | -18.64% |
| 2021 Q1 | - CAD | 0.0% |
| 2021 Q3 | -61.21 Thousand CAD | -0.9% |
| 2021 Q4 | -84.74 Thousand CAD | -38.44% |
| 2021 Q2 | -60.66 Thousand CAD | 0.0% |
| 2020 Q2 | - CAD | 0.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q4 | - CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 FY | -225.23 Thousand CAD | -266.38% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 FY | -61.47 Thousand CAD | 4.73% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 FY | -64.52 Thousand CAD | -61.86% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 FY | -39.86 Thousand CAD | -427.05% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 FY | -7564.00 CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 100.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q2 | 80.00 CAD | -68.75% |
| 2010 Q3 | 222.00 CAD | 177.5% |
| 2010 Q4 | -558.00 CAD | -351.35% |
| 2010 Q1 | 256.00 CAD | 100.93% |
| 2009 Q2 | 5369.00 CAD | -58.51% |
| 2009 FY | - CAD | -100.0% |
| 2009 Q3 | 12.88 Thousand CAD | 139.99% |
| 2009 Q4 | -27.49 Thousand CAD | -313.38% |
| 2009 Q1 | 12.94 Thousand CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 FY | 80.3 Thousand CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2006 Q4 | - CAD | -100.0% |
| 2006 FY | - CAD | -100.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2006 Q3 | 35.48 Thousand CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2005 Q1 | 1087.00 CAD | 183.49% |
| 2005 Q2 | 887.00 CAD | -18.4% |
| 2005 Q3 | 18.56 Thousand CAD | 1993.35% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 FY | 5284.00 CAD | -88.07% |
| 2004 FY | 44.27 Thousand CAD | -66.64% |
| 2004 Q4 | -1302.00 CAD | -101.55% |
| 2004 Q3 | 83.85 Thousand CAD | 6190.92% |
| 2004 Q2 | 1333.00 CAD | -67.64% |
| 2004 Q1 | 4119.00 CAD | -81.98% |
| 2003 Q1 | 1446.00 CAD | -48.54% |
| 2003 Q3 | 105.73 Thousand CAD | 3820.58% |
| 2003 FY | 132.74 Thousand CAD | 685.65% |
| 2003 Q4 | 22.86 Thousand CAD | -78.38% |
| 2003 Q2 | 2697.00 CAD | 86.51% |
| 2002 FY | 16.89 Thousand CAD | -79.22% |
| 2002 Q3 | 3113.00 CAD | 13.53% |
| 2002 Q2 | 2742.00 CAD | -66.69% |
| 2002 Q1 | 8231.00 CAD | 0.0% |
| 2002 Q4 | 2810.00 CAD | -9.73% |
| 2001 FY | 81.32 Thousand CAD | 0.0% |
| 2000 FY | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Appili Therapeutics Inc. | 813.74 Thousand CAD | 154.753% |
| Eupraxia Pharmaceuticals Inc. | -209.91 Thousand CAD | -112.257% |
| Helix BioPharma Corp. | -14 Thousand CAD | -3082.507% |
| Microbix Biosystems Inc. | 7.48 Million CAD | 105.956% |
| Medicenna Therapeutics Corp. | -5000.00 CAD | -8811.02% |
| Satellos Bioscience Inc. | -8.81 Million CAD | 94.947% |
| Oncolytics Biotech Inc. | -403 Thousand CAD | -10.559% |